- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01880827
Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery (GIP-PET)
The Effects of Glucose-dependent Insulinotrophic Peptide (GIP) and Glucagon-like Peptide 1 (GLP-1) on Splanchnic Redistribution of Blood Flow at Postprandial State and After Roux-en-Y Gastric Bypass and Sleeve
Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems.
Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.
The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems, including type 2 diabetes mellitus (T2DM). In T2DM, body is unable to response to circulating insulin levels, which ultimately destroys pancreatic β-cells, leading to chronic hyperglycaemia with ensuing consequences
Intestine is able to produce endocrinologically active substances, which affect to body's intermediary metabolism. One of these substances in glucose-dependent insulinotrophic polypeptide (GIP, part of the incretin family), which potentiates the release of insulin postprandially. However, recent evidence suggests, that GIP may have more harmful than beneficial role in the pathogenesis: it has been shown that GIP participates in the development of insulin resistance, the key defect in the process of metabolic dysfunction. GIP may also regulate postprandial redistribution of splanchnic blood flow which might act in the body's nutrition handling [8].
Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Most established of these procedures is a Roux-en-Y gastric bypass (RYGB), where duodenum and proximal jejunum is bypassed. Clinical and research evidence shows that shortly (before any significant weight loss) after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin¬, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis.
Positron emission tomography (PET) is a modern imaging technique, which can be used to study perfusion and metabolism of different organs non-invasively. When radiowater measurement is combined with [15O]CO, both tissues specific perfusion and blood volume can be measured, respectively. When coupled with magnetic imaging (ie. PET-MRI), the volumes-of-interests can be accurately drawn to the desired organs.
The current study is conducted to investigate the vasoactive roles of the GIP. We aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state. Moreover, we hypothesize that the elimination of GIP-effect has a central role in the improved intermediary metabolism observed after bariatric surgery procedures, and that part this change is mediated by changes in splanchnic circulation. Furthermore, we investigate the effect of GLP-1 (glucagon-like peptide 1, another member of incretin family) on splanchnic circulation.
In the present study intestinal, hepatic and pancreatic blood flow and volume are measured using [15O]H2O- and [15O]CO radiotracers and PET-MRI imaging in healthy normal weight volunteers (n = 20, BMI ≤ 27 kg/m2) and in morbidly obese T2DM patients (n = 30, BMI ≤ 35 kg/m2) before and after the bariatric surgery operation. The PET imaging will be performed at fasting state but also separately either during 1) mixed meal solution (MMS), 2) GIP-, or 3) GLP-1-infusion. Also abdominal subcutaneous and visceral adipose tissue, intestinal and hepatic tissue samples will be collected.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Turku, Finland, 20540
- Turku univercity hospital, PET center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI > 35 kg/m2
- Type 2 diabetes mellitus (fasting glucose more than 7 mmol/l)
- Age: 18-60 years
- Previous, carefully planned, conservative treatments for obesity have failed
Exclusion Criteria:
- BMI over 60 kg/m2
- Weight more than 170 kg
- Waist circumference > 150 cm
- Insulin treatment requiring type 2 diabetes mellitus
- Mental disorder or poor compliance
- Eating disorder or excessive use of alcohol
- Active ulcus-disease
- Pregnancy
- Past dose of radiation
- Presence of any ferromagnetic objects that would make MR imaging contraindicated
- Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
Inclusion criteria for the control group
- BMI 18-27 kg/m2
- Age 18-60 years
- Fasting plasma glucose less than 6.1 mmol/l
- Normal glucose tolerance test (OGTT)
Exclusion criteria for the control group
- Blood pressure > 140/90 mmHg
- Any chronic disease
- Mental disorder or poor compliance
- Any chronic medical defect or injury which hinder/interfere everyday life
- Eating disorder or excessive use of alcohol
- Pregnancy
- Past dose of radiation
- Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
- Presence of any ferromagnetic objects that would make MR imaging contraindicated
- Smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Royx-en-Y surgery
Mixed meal test (MMS) with flow studies before and 2 months after the operation
|
Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG.
After the surgery, subjects are controlled in hospital ward for approximately three days.
Blood flow and volume during infusion
Blood flow and volume after meal solution
|
Active Comparator: Control
Healthy volunteer group, GIP, GLP-1 and MMS studies
|
Blood flow and volume during infusion
Blood flow and volume after meal solution
Blood flow and volume during infusion
|
Experimental: Sleeve gastrectomy
Mixed meal test (MMS) with flow studies before and 2 months after the operation
|
Blood flow and volume during infusion
Blood flow and volume after meal solution
as in RYGS group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Splanchnic blood flow
Time Frame: 24 months
|
Flow is measured using radiowater H2O and PET
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GIP and GLP-1 blood concetrations
Time Frame: 24 months
|
Blood concentrations are measured from samples
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pirjo Nuutila, Prof, PET centre, Turku
Publications and helpful links
General Publications
- Saari T, Koffert J, Honka H, Kauhanen S, U-Din M, Wierup N, Lindqvist A, Groop L, Virtanen KA, Nuutila P. Obesity-associated Blunted Subcutaneous Adipose Tissue Blood Flow After Meal Improves After Bariatric Surgery. J Clin Endocrinol Metab. 2022 Jun 16;107(7):1930-1938. doi: 10.1210/clinem/dgac191.
- Honka H, Koffert J, Kauhanen S, Teuho J, Hurme S, Mari A, Lindqvist A, Wierup N, Groop L, Nuutila P. Bariatric Surgery Enhances Splanchnic Vascular Responses in Patients With Type 2 Diabetes. Diabetes. 2017 Apr;66(4):880-885. doi: 10.2337/db16-0762. Epub 2017 Jan 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-002689-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Roux-en-Y
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Nanfang Hospital of Southern Medical UniversityUnknownStomach Neoplasms | Minimally Invasive Surgery | AnastomosisChina
-
Jilin UniversityUnknown
-
Gangnam Severance HospitalCompletedGastric Cancer | Diabetes Mellitus Type 2 in NonobeseKorea, Republic of
-
Fudan UniversityUnknown
-
University Hospital, LilleMinistry of Health, FranceRecruitingDiabetes Mellitus Type 2 in ObeseFrance
-
CARLOS ZERRWECK LOPEZCompletedRoux-en-Y Gastric Bypass | Bariatric Surgery | Metabolic SurgeryMexico
-
TingBo LiangUnknownHepatolithiasis | Sphincter of Oddi LaxityChina
-
West China HospitalUnknownQuality of Life | Gastric Cancer | Complication | Roux-en-y Anastomosis Site | Gastric Anastomosis (Site)China
-
University Hospital, MontpellierCompletedHypertension | ObesityFrance